We then used these profiles to evaluate several comparisons: metabolomic differences between AML patients and controls; metabolomic differences between patients based on the type of response to induction therapy, namely, CR or NR; metabolomic differences before and after induction in a group of responders; metabolomic differences between patients in different risk groups according to the 2017 ELN recommendations for the diagnosis and management of AML11; and metabolomic differences between AML patients with and without FLT3-ITD mutation. Here, FLT3 is linked to acute myeloid leukemia.